

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
SII NANOTECHNOLOGY USA INC.		09/17/2009	CORPORATION: CALIFORNIA

RECEIVING PARTY DATA

Name:	GAMMA MEDICA-IDEAS (USA), INC.
Street Address:	19355 Business Center Drive, Suite 8
City:	Northridge
State/Country:	CALIFORNIA
Postal Code:	91324
Entity Type:	CORPORATION: CALIFORNIA

PROPERTY NUMBERS Total: 7

Property Type	Number	Word Mark
Registration Number:	2690866	LUMAGEM
Registration Number:	2766480	YMI GAMMA MEDICA
Registration Number:	2690867	LUMAGEM
Registration Number:	2831741	GAMMACAM/OR
Registration Number:	2885050	MICROSPECT
Registration Number:	2799252	X-SPECT
Registration Number:	2717622	A-SPECT

CORRESPONDENCE DATA

Fax Number: (818)444-6327
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Phone: 818-444-4500
 Email: kchoi@biztechlaw.com
 Correspondent Name: Stubbs Alderton & Markiles Attn: K. Choi
 Address Line 1: 15260 Ventura Blvd., 20th Floor

OP \$190.00 2690866

900143477

**TRADEMARK
 REEL: 004063 FRAME: 0804**

Address Line 4: Sherman Oaks, CALIFORNIA 91403

ATTORNEY DOCKET NUMBER:

GAMMA

NAME OF SUBMITTER:

Kirstin Choi

Signature:

/Kirstin Choi/

Date:

09/17/2009

Total Attachments: 5

source=SII NanoTechnology USA Inc. IP Release - GMI USA 9-17-09#page1.tif

source=SII NanoTechnology USA Inc. IP Release - GMI USA 9-17-09#page2.tif

source=SII NanoTechnology USA Inc. IP Release - GMI USA 9-17-09#page3.tif

source=SII NanoTechnology USA Inc. IP Release - GMI USA 9-17-09#page4.tif

source=SII NanoTechnology USA Inc. IP Release - GMI USA 9-17-09#page5.tif

TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENT AND TRADEMARK RIGHTS

This TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENT AND TRADEMARK RIGHTS (this “**Termination and Release**”) is granted by SII NANOTECHNOLOGY USA INC., a California corporation with an office at 19865 Nordhoff Street, Northridge, California 91324, as collateral agent for certain Obligees referred to in the Collateral Agency Agreement defined below (the “**Collateral Agent**”), in favor of GAMMA MEDICA-IDEAS (USA), INC., a California corporation, with an office at 19355 Business Center Drive, Suite 8, Northridge, California 91324 (the “**Releasee**”).

WHEREAS, pursuant to that certain Security Agreement dated as of February 12, 2008, made by the Releasee in favor of the Collateral Agent (the “**Security Agreement**”), a security interest (the “**Security Interest**”) was granted in certain collateral, including the Collateral (as defined below);

WHEREAS, pursuant to that certain Patent and Trademark Security Agreement dated as of February 12, 2008, made by the Releasee in favor of the Collateral Agent (the “**Patent and Trademark Security Agreement**”), the Releasee, by reference to the Security Agreement, reaffirmed its intent to grant a Security Interest to the Collateral Agent specifically in the Collateral;

WHEREAS, the Security Interest was recorded in the United States Patent and Trademark Office on February 21, 2008; and

WHEREAS, the Collateral Agent now desires to terminate and release the entirety of its Collateral;

NOW, THEREFORE, for good and valuable consideration, including the satisfaction of all obligations, indebtedness and liabilities secured by the Collateral pursuant to the Security Agreement and the Patent and Trademark Security Agreement, the receipt and adequacy of which are hereby acknowledged, and upon the terms set forth in this Termination and Release, the Collateral Agent hereby states as follows:

1. Definitions.

1.1. The term “**Collateral**” means the following property, in each case whether now or hereafter existing or arising or in which Releasee now has or hereafter owns, acquires or develops an interest and wherever located:

(i) all patents and patent applications, domestic or foreign, all licenses relating to any of the foregoing and all income and royalties with respect to any licenses (including such patents and patent applications as described in Schedule A), all rights to sue for past, present or future infringement thereof, all rights arising therefrom and pertaining thereto and all reissues, divisions, continuations, renewals, extensions and continuations-in-part thereof;

(ii) all state (including common law), federal and foreign trademarks, service marks and trade names, and applications for registration of such trademarks, service marks and trade names, all licenses relating to any of the foregoing and all income and royalties with respect to any licenses (including such marks, names and applications as described in Schedule B), whether registered or unregistered and wherever registered, all rights to sue for past, present or future infringement or unconsented use thereof, all rights arising therefrom and pertaining thereto and all reissues, extensions and renewals thereof;

(iii) the entire goodwill of or associated with the businesses now or hereafter conducted by Releasee connected with and symbolized by any of the aforementioned properties and assets;

(iv) all commercial tort claims associated with or arising out of any of the aforementioned properties and assets;

(v) all accounts, all intangible intellectual or other similar property and other general intangibles associated with or arising out of any of the aforementioned properties and assets and not otherwise described above, including all license payments and payments under insurance (whether or not Collateral Agent is the loss payee thereof) or any indemnity, warranty or guaranty payable by reason of loss or damage to or otherwise with respect to the foregoing Collateral; and

(vi) all products, proceeds and supporting obligations of or with respect to any and all of the foregoing Collateral.

1.2. The term “**Collateral Agency Agreement**” means that certain Collateral Agency Agreement, dated February 12, 2008, among SII NanoTechnology USA Inc. and SII NanoTechnology Inc., as Obligees, and SII NanoTechnology USA Inc., as Collateral Agent.

2. Release of Security Interest. The Collateral Agent hereby terminates, releases and discharges the entirety of its Security Interest in the Collateral, and any right, title or interest that the Collateral Agent may have in such Collateral shall hereby cease and become void.

3. No Assignment. Collateral Agent represents and warrants to Releasee that neither Collateral Agent nor any Obligee has in any way conveyed, granted, transferred, encumbered, hypothecated or otherwise pledged or disposed of any of the right, title or interest granted to Collateral Agent under the Patent and Trademark Security Agreement to any party other than Releasee.

4. Further Assurances. The Collateral Agent hereby agrees to execute, acknowledge and deliver any further documents and to do such other acts as may be reasonably necessary to effect the release of the Security Interest contemplated hereby.

[Signatures Appear on the Following Page]

IN WITNESS WHEREOF, the undersigned has executed this Termination and Release by its duly authorized officer as of September 17, 2009.

SII NANOTECHNOLOGY USA INC.,
as Collateral Agent

By: 

Name: Masaharu Kawamura

Title: President CEO

[Termination and Release Signature Page]

SCHEDULE A

Issued U.S. Patents of Releasee

<u>Patent No.</u>	<u>Issue Date</u>	<u>Inventor(s)</u>	<u>Title</u>
None.			

Pending U.S. Patent Applications of Releasee

<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor</u>	<u>Title</u>
11/985,269	11/13/2007	Doug Wagenaar and Brad Patt (formal assignment document not yet executed and recorded)	Method and system for combining magnetic resonance and nuclear imaging
11/985,820	11/16/2007	*Co-Owned by Gamma Medica-Ideas (USA), Inc. and Johns Hopkins University (formal assignment document not yet executed)	Multi-aperture single photon emission computed tomography (SPECT) imaging apparatus
60/859,585	11/17/2006	*Co-Owned with Johns Hopkins University	Multi-Aperture Single Photon Emission Computed Tomography (SPECT) Imaging Apparatus SynapSPECT - Multiple Pinhole Aperture

SCHEDULE B

U.S. Registered Trademarks of Releasee

<u>Registration No.</u>	<u>Registration Date</u>	<u>Filing Date</u>	<u>Registered Owner</u>	<u>Mark</u>
2,690,866	2/25/2003	7/1/2002	Gamma Medica, Inc	LUMAGEM
2,766,480	9/23/2003	7/1/2002	Gamma Medica, Inc	YMI GAMMA MEDICA
2,690,867	2/25/2003	7/1/2002	Gamma Medica, Inc	LUMAGEM and design
2,831,741	4/13/2004	6/2/2003	Gamma Medica, Inc	GAMMACAM/OR
2,885,050	9/14/2004	5/14/2002	Gamma Medica, Inc.	MICROSPECT
2,799,252	12/23/2003	5/14/2002	Gamma Medica, Inc.	X-SPECT
2,717,622	5/20/2003	7/25/2002	Gamma Medica, Inc	A-SPECT

Pending U.S. Trademark Applications of Releasee

<u>Application No.</u>	<u>Filing Date</u>	<u>Applicant</u>	<u>Mark</u>
None.			